These particular histopathologic features were also found close to tumor areas with necrosis and foci of microvascular proliferation and led us to request a further molecular test for diagnostic confirmation and for the search of FGFR3-TACC3 fusion, whose presence has not only a speculative but also a practical function as it identifies a subset of patients with a slightly better prognosis than those affected by conventional GBM, IDHwt and who could benefit from a targeted therapy with FGFR kinase inhibitors. The gene discussed is FGFR3; the disease is glioblastoma.